Drug hope for sepsis uncovered

BBC Published Jun 4, 2010 Reviewed Jul 3, 2026 ✓ Reviewed by citations.press editors

Sepsis affects 20 million people worldwide every year.

Immune cells from patients with severe sepsis produce abnormally high levels of the enzyme SphK1.

Treatment with enzyme-blocking drugs cut the risk of death in mice with septic shock.

Professor Alirio Melendez, study leader from the University of Glasgow, stated that sepsis incidence is increasing and clinical treatments remain inadequate.

John Heyworth, president of the College of Emergency Medicine, emphasized that early diagnosis is key to improving sepsis survival and described sepsis as a time-critical condition.

John Heyworth, president of the College of Emergency Medicine, said early diagnosis is a key factor in improving survival in people with sepsis.

John Heyworth stated that sepsis is a time-critical condition with a window for effective intervention.

As many as 50% of people with septic shock die.

There are an estimated 31,000 cases a year of severe sepsis in England and Wales.

Blocking the enzyme SphK1 reduced the inflammatory signals sent out by immune cells.

Treated mice were protected from multi-organ failure and were much better at clearing bacterial infection than untreated mice.

Scientists have uncovered a potential new treatment for blood poisoning.

Experiments by a team in Glasgow show that blocking a molecule, previously found to be activated during septic shock, cuts the risk of death in mice.

It is hoped the finding, published in Science, external, could lead to a wider range of drugs for the condition which affects 20 million people worldwide every year.

As many as 50% of people with septic shock die, figures show.

In England and Wales there are an estimated 31,000 cases a year of severe sepsis, which is a catastrophic immune system reaction to infection leading to organ failure.

Patients need to be admitted to intensive care so their organs can be supported while the infection is treated.

In the latest study researchers built on previous work showing that an enzyme called SphK1 is triggered during the inflammation that occurs in septic shock.

They showed that immune cells from patients with severe sepsis produced abnormally high levels of the enzyme and that blocking it from reduced the inflammatory signals sent out by the cells.

Using drugs which block the enzyme, they showed that treatment cut the risk of death in mice with the condition.

The treated mice were also protected from multi-organ failure, and were much better at clearing the bacterial infection than untreated mice.

Study leader Professor Alirio Melendez, from the University of Glasgow, said drugs which block the enzyme may become useful treatments.

"The incidence of sepsis is on the increase and clinical treatments are still inadequate so a medical breakthrough of this kind is timely and will hopefully lead to a way to treat this killer condition."

John Heyworth, president of the College of Emergency Medicine, said the results were very interesting but one of the key factors in improving survival in people with sepsis was getting an early diagnosis.

He said people end up in hospital because they are very unwell but there may not be an obvious source of infection.

"It's important to identify sepsis early and treat it aggressively.

"There is a window when you can make a big difference - it is a time-critical condition."

This article was originally published by BBC ↗. citations.press indexes the source-backed facts above and links to the original. Something wrong? Corrections policy · Report an error